

# UC Santa Cruz

## UC Santa Cruz Previously Published Works

### Title

Membrane orientation and oligomerization of the melanocortin receptor accessory protein 2

### Permalink

<https://escholarship.org/uc/item/590154x1>

### Journal

Journal of Biological Chemistry, 295(48)

### ISSN

0021-9258

### Authors

Chen, Valerie  
Bruno, Antonio E  
Britt, Laura L  
[et al.](#)

### Publication Date

2020-11-01

### DOI

10.1074/jbc.ra120.015482

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



# Membrane orientation and oligomerization of the melanocortin receptor accessory protein 2

Received for publication, August 3, 2020, and in revised form, September 8, 2020. Published, Papers in Press, September 17, 2020, DOI 10.1074/jbc.RA120.015482

Valerie Chen<sup>1</sup>, Antonio E. Bruno<sup>1</sup>, Laura L. Britt<sup>1</sup>, Ciria C. Hernandez<sup>2</sup>, Luis E. Gimenez<sup>2</sup>, Alys Peisley<sup>2</sup>, Roger D. Cone<sup>2</sup> , and Glenn L. Millhauser<sup>1,\*</sup>

From the <sup>1</sup>Department of Chemistry and Biochemistry, University of California, Santa Cruz, California, USA, and the <sup>2</sup>Life Sciences Institute and Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA

Edited by Henrik G. Dohlman

The melanocortin receptor accessory protein 2 (MRAP2) plays a pivotal role in the regulation of several G protein-coupled receptors that are essential for energy balance and food intake. MRAP2 loss-of-function results in obesity in mammals. MRAP2 and its homolog MRAP1 have an unusual membrane topology and are the only known eukaryotic proteins that thread into the membrane in both orientations. In this study, we demonstrate that the conserved polybasic motif that dictates the membrane topology and dimerization of MRAP1 does not control the membrane orientation and dimerization of MRAP2. We also show that MRAP2 dimerizes through its transmembrane domain and can form higher-order oligomers that arrange MRAP2 monomers in a parallel orientation. Investigating the molecular details of MRAP2 structure is essential for understanding the mechanism by which it regulates G protein-coupled receptors and will aid in elucidating the pathways involved in metabolic dysfunction.

The melanocortin receptor accessory protein 2 (MRAP2) regulates several G protein-coupled receptors (GPCRs) that play critical roles in the regulation of energy homeostasis, and heterozygous MRAP2 variants have been identified in obese humans (1–4). MRAP2 modulates the signaling of the melanocortin-4 receptor (MC4R), one of the five GPCRs in the melanocortin receptor family (1, 5). MC4R and MRAP2 are expressed in the paraventricular nucleus of the hypothalamus, a primary region for the control of food intake. MC4R is essential for energy homeostasis, and heterozygous mutations in MC4R are the most common monogenic cause of human obesity (6, 7). In zebrafish, two MRAP2 genes allow for developmental control of MC4R signaling (5). Zebrafish MRAP2a, which is restricted to larval development, suppresses MC4R signaling, whereas MRAP2b, which is expressed in adult zebrafish, increases MC4R's sensitivity to its agonist  $\alpha$ -melanocyte-stimulating hormone. Furthermore, MRAP2 enhances signaling through MC4R *in vitro*, and overexpression of MRAP2 in MC4R-containing paraventricular nucleus neurons leads to a reduction in food intake and increased energy expenditure in female mice (1, 8). Targeted deletion of MRAP2 in mice results in an obese phenotype; however, mice lacking only MC4R are more obese than mice lacking both MRAP2 and MC4R (1). This suggests that there are other mechanisms by which

MRAP2 also promotes feeding. It is now understood that MRAP2's regulation over GPCRs is not limited to the melanocortin receptor family. MRAP2 has been shown to promote feeding through inhibition of the prokineticin receptor-1, as well as to decrease food intake through inhibition of the orexin receptor (9, 10). Additionally, MRAP2 regulates hunger sensing by potentiating ghrelin signaling through its interaction with growth hormone secretagogue receptor 1a (GHSR1a) in the arcuate nucleus of the hypothalamus (ARC) (11, 12).

MRAP2, as well as its well-studied homolog MRAP1, are single-pass transmembrane proteins that can insert into the membrane in both orientations: N-terminal domain out or in (Fig. 1, A and B) (13–15). Like MRAP1, MRAP2 can homodimerize and form anti-parallel dimers (16, 17). MRAP2 and MRAP1 are the only two proteins in the eukaryotic proteome that are currently known to exhibit this unusual membrane orientation. The orientation of most membrane proteins is predicted by the “positive-inside rule,” in which the charged amino acids flanking the transmembrane domain determine the overall orientation such that the more positive region faces the cytosol (18, 19). Based on this rule, MRAP1 is predicted to insert into the membrane in both orientations, which agrees with experimental data. Using the same line of logic, MRAP2 is predicted to have its N-terminal domain in the cytosol. Nevertheless, recent findings show that MRAP2 has dual topology. It is evident that the positive-inside rule is not sufficient for explaining MRAP2's membrane orientation.


Despite the important role MRAP2 plays in the modulation of energy homeostasis, the sequence features within MRAP2 that dictate membrane orientation and dimerization are unknown. MRAP1's membrane orientation and oligomeric state are dependent on a short polybasic segment adjacent to the transmembrane domain (13, 14). Although this motif is conserved in MRAP2, we show that this sequence does not dictate MRAP2's membrane orientation or dimerization in cell culture. Additionally, using truncation mutations, we identify the transmembrane domain of MRAP2 as the minimal dimerization domain. Finally, we show that contrary to the assumption that MRAP2 can only form anti-parallel dimers, MRAP2 can form parallel dimers as well as higher-order oligomers. Our results not only highlight important differences between MRAP1 and MRAP2 but also offer new insight into MRAP2 structure. Understanding the molecular details that determine MRAP2's oligomeric state and membrane orientation will aid

This article contains supporting information.

\* For correspondence: Glenn L. Millhauser, glennm@ucsc.edu.



## Membrane oligomerization of MRAP



**Figure 2. The conserved motif required for dual topology and dimerization of MRAP1 is not required for dual topology and dimerization of MRAP2.** A, both the N terminus and C terminus of MRAP2 WT and  $\Delta$ 38–44 are detected from intact, unpermeabilized HEK293T cells, as seen by immunofluorescence. FLAG-tagged MRAP2 is shown in pink, and the nucleus is shown in blue. Scale bars, 100  $\mu$ m. B, flow cytometry was used to determine the N-terminal to C-terminal fluorescence ratio for MRAP2 WT,  $\Delta$ 38–44, and RAMP3 from intact cells expressing N-terminally tagged constructs and C-terminally tagged constructs. Expression levels for each construct were normalized using parallel experiments with permeabilized cells. The data represent the means from three independent experiments. Error bars show S.D. Statistical significance of differences was analyzed by *t* test. \*\*, *p* < 0.01 versus MRAP2. C, immunoblot showing two protein species for FLAG-MRAP2 and FLAG- $\Delta$ 38–44. Treatment with peptide:N-glycosidase F (PNGase F) results in a single, deglycosylated protein species. D, immunoblot showing co-immunoprecipitation of HA- and FLAG-tagged MRAP2 and HA- and FLAG-tagged  $\Delta$ 38–44. IP, immunoprecipitation; WB, Western blotting. UT, Untransfected.

dimers or higher-order oligomers or associate through noncovalent interactions with other membrane proteins (Fig. 2D). The same experiment was performed in Chinese hamster ovary (CHO) cells and yielded the same results (Fig. S2). Overall, these results indicate that the conserved polybasic motif that is required for dual topology, and dimerization in MRAP1 is not required for either dual topology or dimerization/association of MRAP2.

### MRAP2 dimerizes through its transmembrane domain

MRAP2 is known to form dimers or higher-order oligomers, but the dimerization domain has not been identified. To identify the dimerization domain, constructs were created that either truncate the C-terminal domain (NTD-TM), the N-terminal domain (TM-CTD), or both the N- and C-terminal domains, leaving just the transmembrane domain (TM). HEK293T cells were co-transfected with both FLAG and HA epitope-tagged constructs in the following combinations: TM-CTD + TM-CTD, NTD-TM + NTD-TM, NTD-TM + TM-CTD, and TM + TM. Co-immunoprecipitation, followed by Western blotting show that neither the N-terminal domain nor the C-terminal domain are required for dimerization or association (Fig. 3A). Specifically, TM-CTD can be co-immunoprecipitated with itself and with



NTD-TM (Fig. 3A, fourth, sixth, and seventh lanes), and NTD-TM can be co-immunoprecipitated with itself (Fig. 3A, fifth lane). Finally, the transmembrane domain can also be co-immunoprecipitated with itself (Fig. 3A, eighth lane). The experiment was also performed in CHO cells and yielded the same results (Fig. S2). Based on these results MRAP2 dimerizes or associates through its transmembrane domain.

The GXXXG motif is common in transmembrane helix interactions (21, 22). We also investigated whether the glycine residues within the transmembrane domain of MRAP2 are required for dimerization by mutating the glycine residues that make up this motif to leucine residues (G48L + G52L). Co-immunoprecipitations from cell lysates followed by immunoblotting also show that the glycine residues within the transmembrane domain are not required for MRAP2 dimerization or association (Fig. 3A, ninth lane).

### MRAP2 can form parallel dimers and higher-order oligomers

Based on bimolecular fluorescence complementation experiments by Sebag and Hinkle, MRAP2, like MRAP1, forms anti-parallel dimers (16). Although previous experiments show that MRAP1 forms exclusively anti-parallel dimers and does not form parallel dimers, it is unclear whether this holds true for






**Figure 3. MRAP2 dimerizes through its transmembrane domain.** *A*, HEK293T cells are co-transfected with HA- and FLAG-tagged versions of the following MRAP2 constructs: N-terminal domain truncation (*TM-CTD*), C-terminal domain truncation (*NTD-TM*), the transmembrane domain alone (*TM*), or a mutant that replaces the glycine residues within the transmembrane domain with leucine residues (*G48L + G52L*). Co-immunoprecipitations from cell lysates followed by immunoblotting show that neither the N-terminal domain, the C-terminal domain, nor the glycine residues in the transmembrane domain are required for dimerization of MRAP2. *B*, schematic depicting the co-immunoprecipitated HA- and FLAG-tagged MRAP2 dimers. *IP*, immunoprecipitation; *WB*, Western blotting.

MRAP2. To determine whether MRAP2 forms parallel dimers, a NanoBiT protein–protein interaction assay was performed. The NanoBiT system is composed of a large BiT (LgBiT) and a small BiT (SmBiT) that have very little to no luciferase activity

on their own. However, when LgBiT and SmBiT are in close proximity within the cell, the functional luciferase will then generate a luminescent signal at even low protein expression levels, driven by weak HSV-TK promoter. The low intrinsic affinity

## Membrane oligomerization of MRAP



**Figure 4. MRAP2 forms parallel dimers or higher-order oligomers.** *A*, NanoBiT signal from live cells co-expressing MRAP2-SmBiT with LgBiT-MRAP2 or MRAP2-SmBiT with MRAP-LgBiT. All mutants have both SmBiT and LgBiT as C-terminal fusions. SmBiT-PRKACA is a cytosolic control construct with SmBiT fused to cAMP-dependent protein kinase catalytic subunit  $\alpha$ . The data represent the means from at least three independent experiments. Error bars show S.D. Statistical significance was analyzed by one-way analysis of variance ( $F(6, 59) = 18.75, p < 0.0001$ ) followed by a Dunnett's multiple comparisons test. Dunnett's test adjusted  $p$  values are shown. \*\*\*\*,  $p < 0.0001$ ; \*\*,  $p < 0.01$  versus WT-LgBiT, SmBiT-PRKACA. *B*, schematic showing reconstituted NanoLuciferase from MRAP2 parallel dimers (left) and anti-parallel dimers (right). RLU, relative light units.


between the isolated SmBiT and LgBiT lessens the likelihood of spurious dimerization driven by these segments. The following combinations of DNA were transfected into HEK293T cells: MRAP2-LgBiT + SmBiT-PRKACA, LgBiT-MRAP2 + SmBiT-PRKACA, LgBiT-MRAP2 + MRAP2-SmBiT, and MRAP2-LgBiT + MRAP2-SmBiT. PRKACA is a noninteracting cytosolic protein that is used as a negative control. Surprisingly, when MRAP2-LgBiT and MRAP2-SmBiT are transfected together, we see a NanoBiT luminescence signal that is significantly higher than the negative control (Fig. 4A). These results show that the C-terminal domains of MRAP2 are in close proximity to each other in live cells, consistent with dimerization (Fig. 4B). MRAP2  $\Delta 38-44$ , TM-CTD, NTD-TM, TM, and G48L+G52L with C-terminal LgBiT and C-terminal SmBiT also resulted in a significant NanoBiT luminescence signal when compared with the negative control, and these results are consistent with the co-immunoprecipitation experiments. Unexpectedly, when LgBiT-MRAP2 and MRAP2-SmBiT are transfected together, there is less NanoBiT signal than the negative control. The absence of a significant NanoBiT signal from the anti-parallel orientation may be due to the inherent size difference between the N- and C-terminal domains of MRAP2, because the C-terminal domain is significantly larger than the N-terminal domain. Once MRAP2 multimers are positioned in the membrane, the shorter length of the N-terminal domain may not favorably allow for a LgBiT and SmBiT interaction. Overall, these results indicate that the C-terminal domains of MRAP2 are in close proximity in the cell but does not exclude anti-parallel MRAP2 dimers.

To further test the findings above and investigate whether MRAP2 forms higher-order oligomers, whole-cell cross-linking and blue native PAGE were employed. Whole cells expressing FLAG-MRAP2 were cross-linked with a membrane-permeable, lysine-reactive cross-linker, and the resulting whole-cell lysates

were analyzed by SDS-PAGE and Western blotting (Fig. 5A). The presence of higher-molecular-weight bands with the apparent molecular weights of cross-linked dimeric and trimeric MRAP2 suggests that MRAP2 forms higher-order oligomers that can be cross-linked in whole cells. MRAP2 containing lysates from non-cross-linked cells were also separated on a polyacrylamide gel under native conditions with varying concentrations of *n*-dodecyl- $\beta$ -maltoside detergent (Fig. 5B). Consistent with the cross-linking results, non-cross-linked MRAP2 forms higher-molecular-weight structures. These structures are most likely dimers, tetramers, and octamers based on the molecular weights of the bands. Because native protein shape and the amount of bound detergent will affect protein complex mobility through the gel matrix, the molecular weights predicted from native gels are approximate (23, 24). Accordingly, we cannot rule out that the higher-molecular-weight bands arise from MRAP2 associating with other membrane proteins. If the high molecular weight bands are due to MRAP2 alone, we note that the absence of higher-order oligomer bands such as tetramers and octamers in the cross-linking experiment are likely a result of incomplete cross-linking of higher-order structures. Similarly, the presence of trimer in Fig. 5A may be due to incomplete cross-linking of a tetrameric structure. In summary, these results indicate that MRAP2 forms parallel dimers and higher-order oligomers such that the C-terminal domains of MRAP2 proteins are in close proximity in the membrane (Fig. 5C).

## Discussion

The N-terminal and transmembrane domains of MRAP2 and MRAP1 are highly conserved and the N-terminal domain of MRAP1 is essential for its dual topology and homodimerization. However, we show that the mechanism that regulates MRAP2



**Figure 5. MRAP2 forms higher-order oligomers.** A, HEK293T cells transfected with FLAG-MRAP2 were incubated with an irreversible cross-linker (DSG or DSS). Proteins in cell lysate were separated by SDS-PAGE and immunoblotted. B, HEK293T cells expressing FLAG-MRAP2 were solubilized with varying concentrations of DDM and analyzed by blue native PAGE and immunoblotted. The band of ~66 kDa is the approximately the molecular mass of a FLAG-MRAP2 dimer. C, schematic showing possible MRAP2 higher-order oligomers. WB, Western blotting.

dimerization is distinct from that of MRAP1. Deletion of the conserved polybasic motif that dictates MRAP1's membrane orientation from MRAP2 does not abolish dual membrane orientation nor dimerization of MRAP2. The positive-inside rule that predicts the orientation of transmembrane domains is based on ~15 residues on either side of the transmembrane domain and establishes that the more positively charged side will end up on the cytosolic side of the plasma membrane (18, 19). In fact, single-point mutations in dual-topology membrane proteins from bacteria that have a near zero charge bias can shift the orientations of these proteins (25). Previous experiments that investigated MRAP1's membrane topology are consistent with both the positive-inside rule and algorithms that predict transmembrane helices and membrane topology such as TMHMM (26) (Fig. S3). Approximately half of MRAP1 is glycosylated, supporting the fact that MRAP1 can be inserted into the membrane in both  $N_{\text{exo}}/C_{\text{cyto}}$  and  $N_{\text{cyto}}/C_{\text{exo}}$  orientations. MRAP1's dual topology has also been validated by bimolecular fluorescence complementation experiments and the presence of both N- and C-terminal antibody epitopes on the cell surface (15). Based on the positive-inside rule and computational predictions, MRAP2 is predicted to favor a  $N_{\text{cyto}}/C_{\text{exo}}$  orientation. However, this study, along with previous studies (16), supports MRAP2 having dual topology, contrary to the predicted  $N_{\text{cyto}}/C_{\text{exo}}$  orientation. MRAP2's dual topology defies the positive-inside rule. Our study reveals that the molecular features that dictate MRAP1 and MRAP2 orientations are distinctly different. These differences between MRAP1 and MRAP2 highlight the importance of identifying the mechanism behind MRAP2's dual topology, and this will be the subject of future studies.

MRAP2 has been shown to co-immunoprecipitate with several GPCRs including all five melanocortin receptors, orexin receptor 1 (OX1R), prokineticin receptor 1 (PKR1), and GHSR1a (9–12, 17). MRAP2's role in modulating GHSR1a has now been thoroughly investigated by Rouault *et al.* (12). They show that MRAP2 alters GHSR1a signaling by inhibiting constitutive activity of the receptor, enhancing ghrelin-mediated G protein signaling and inhibiting ghrelin-stimulated recruitment of  $\beta$ -arrestin to GHSR1a. In addition to demonstrating that MRAP2 can bias the signaling of GHSR1a, the regions of MRAP2 responsible for these effects were also elucidated. Specifically, residues 34–43 of the N-terminal domain, the transmembrane domain, and the C-terminal domain of MRAP2 are required for potentiation of GHSR1a, whereas residues 24–33 and the C-terminal domain are important for inhibition of  $\beta$ -arrestin recruitment. These results highlight independent mechanisms of receptor modulation because distinct regions of MRAP2 are required for the enhancement of G protein signaling *versus* the inhibition of  $\beta$ -arrestin recruitment. The C-terminal domain of MRAP2 is highly conserved and is necessary for modulation of OX1R, PKR1, and GHSR1a (10, 12). Although there is sufficient evidence pointing toward the C terminus of MRAP2 as being the most important domain for the regulation of GPCRs, until this point, the regions of MRAP2 that are essential for its homodimerization have not been identified. In this study, we show that MRAP2 dimerizes through its transmembrane domain. Interestingly, the transmembrane domain of MRAP2 does not appear to be necessary for OX1R and PKR1 inhibition but has been shown to play a role in potentiating GHSR1a signaling (10, 12). An obesity-linked mutation



## Membrane oligomerization of MRAP

within the transmembrane of MRAP2 has also been reported (4). Additionally, the transmembrane domain of MRAP1 is essential for MC2R trafficking (13, 14). RAMP1 dimers are inhibited by the presence of the calcitonin receptor–like receptor, and RAMP1 forms heterodimers with calcitonin receptor–like receptor at a 1:1 ratio, suggesting that RAMP1 interacts with this receptor as a monomer (27). A series of MRAP–MC2R or MRAP–MRAP–MC2R fusion proteins were used by Malik *et al.* (28) to show that MRAP1 dimers were required for MC2R activity. It will be interesting to see whether MRAP2 dimerization is required for function in the same manner as MRAP1 or whether MRAP2 binds to GPCRs as a monomer like RAMP1. Because MRAP2 is somewhat promiscuous and appears to interact with several GPCRs, it is possible that the oligomeric state of functional MRAP2 is GPCR-specific. Further experimentation is needed to determine whether MRAP2 dimerization is necessary for its modulation of GPCRs, as well as to identify motifs or residues within the transmembrane domain that facilitate dimerization. Transmembrane helix-packing motifs that consist of small residues occurring every four or seven residues have been identified (21, 22, 29). EmrE, a small bacterial multidrug transporter, forms anti-parallel dimers through conserved glycine residues (30). However, we find that the glycine residues within MRAP2's transmembrane domain are not required for dimerization.

Bimolecular fluorescence complementation experiments that incorporate yellow fluorescent protein (YFP) fragments on the N- and C-terminal ends of MRAP1 show that MRAP1 forms exclusively anti-parallel dimers because YFP can only be reconstituted when fragments are on opposite ends, and there is no YFP complementation when fragments are placed on the same ends of MRAP1 (13, 14, 16). Similar experiments have been performed for MRAP2 supporting anti-parallel MRAP2 dimers. However, there have been no experiments ruling out a parallel orientation for MRAP2 dimers. Surprisingly, we find that the C-terminal domains of MRAP2 are in close proximity in live cells. This suggests that MRAP2 forms parallel dimers or oligomerizes in such a way that brings the C-terminal domains in close proximity. It is important to note that the absence of data supporting an anti-parallel MRAP2 dimer in our experiments does not eliminate the possibility that MRAP2 can form anti-parallel dimers; rather, it is possible that the size difference between the N- and C-terminal domains of MRAP2 prevents the stable reconstitution of the enzyme used in our complementation experiment once MRAP2 is positioned in the membrane.

We also present evidence for higher-order MRAP2 oligomers that may also explain the presence of parallel MRAP2 dimers. At this juncture, it is not clear whether these higher-order oligomers are required for function, and it is possible that the oligomeric state of MRAP2 depends on the local environment that it exists in. MRAP2 has been shown to form dimers that are resistant to reducing and denaturing conditions from mouse tissue immunoblots (17). Similarly, the proteolipid protein, an abundant CNS myelin protein important for the stabilization of myelin membranes, also forms SDS-resistant dimers in the endoplasmic reticulum (31). The proteolipid protein forms higher-order oligomers only after reaching the cell sur-

face. An attractive hypothesis is that MRAP2 facilitates the trafficking of GPCRs to the cell surface, and once at the cell surface, the changes in MRAP2's oligomeric state could act as a molecular switch to tune its regulation over GPCRs.

Currently, there is very little information regarding MRAP2 structure, and it is not uncommon for single-pass transmembrane proteins to have intrinsically disordered domains, making them difficult to study using classic biophysical techniques (32). These disordered regions often have functional importance because this flexibility allows them to interact with multiple protein partners. Although the transmembrane domain of MRAP2 is most likely a transmembrane helix, there is very little predicted secondary structure in the N- and C-terminal domains. Because MRAP2 has been shown to interact with several receptors, it is possible that in the presence of these receptors, MRAP2 adopts a more rigid conformation, allowing high resolution structures to become more obtainable.

MRAP2 and MRAP1 are the only known eukaryotic proteins that adopt a highly unique dual topology in the membrane. Although the N termini and transmembrane domains of these homologs are highly conserved, we show key differences between MRAP2 and MRAP1 membrane orientation and oligomerization. Specifically, the conserved polybasic motif that is essential for MRAP1's anti-parallel orientation and dimerization does not dictate the topology and oligomeric state of MRAP2. Additionally, for the first time, we provide evidence for the transmembrane domain as being the minimal dimerization domain and identify a new parallel orientation for MRAP2 oligomers. Elucidating the molecular framework behind MRAP2 structure will give insight into the mechanisms by which other single-pass transmembrane proteins and accessory proteins modulate their receptors. Furthermore, given the essential role of MRAP2 in the modulation of GPCRs that are critical for the maintenance of energy homeostasis, understanding the structure of MRAP2 will aid in unraveling the complex neural circuitry responsible for the central regulation of energy balance.

## Experimental procedures

### Expression constructs

3×FLAG-tagged WT MRAP2 constructs are in pSF vectors, and 3×HA-tagged RAMP3 expression constructs are in pcDNA3.1 vectors. WT expression constructs were kindly provided by Dr. Roger Cone (University of Michigan, Life Science Institute, Ann Arbor, MI, USA). Mutations in MRAP2 constructs were generated using PCR primer–based site-directed mutagenesis using primers generated manually and by Primer-Designer.com. NanoBit vectors were purchased from Promega (Madison, WI, USA). MRAP2 was cloned into NanoBiT vectors by directional cloning with the following restriction sites: SacI and XhoI for C-terminal LgBiT and SmBiT and SacI and NheI for N-terminal LgBiT and SmBiT. All constructs were verified by DNA sequencing.

### Cell culture and transfections

HEK293T cells (ATCC CRL-3216, lot no. 62729596) were cultured in Dulbecco's modified Eagle's medium, and CHO



cells were cultured in F-12 medium. Both cell lines were cultured in media supplemented with 10% fetal bovine serum and GlutaMAX from Life Technologies at 37 °C in 5% CO<sub>2</sub>. The cells were transfected with Lipofectamine 2000 DNA transfection reagent from Invitrogen 18–24 h after plating. All experiments were performed 24 h post-transfection.

### Co-immunoprecipitation and Western blotting

HEK293T cells were co-transfected with N-terminally HA-tagged and N-terminally FLAG-tagged MRAP2 WT or mutant constructs using Lipofectamine 2000 following the manufacturer's instructions. After 24 h post-transfection, the cells were washed with ice-cold PBS (pH 7.4) and lysed with 0.2% *n*-dodecyl- $\beta$ -maltoside (DDM) in PBS with EDTA and HALT protease inhibitors (Pierce) added. The lysed cells were incubated on ice for 30 min, and the lysate was clarified at 17,000  $\times g$  at 4 °C for 25 min. Protein concentrations were determined using a BCA protein quantitation kit (Pierce) according to the manufacturer's instructions. Samples treated with peptide:*N*-glycosidase F (New England Biolabs, Ipswich, MA, USA) were treated according to the manufacturer's instructions under denaturing reaction conditions. For immunoprecipitations, lysates were incubated with either anti-FLAG M2-agarose beads (Sigma-Aldrich) or anti-HA HA-7-agarose beads (Sigma-Aldrich) overnight at 4 °C with end-over-end mixing. The same volume of lysate was used for anti-FLAG and anti-HA pulldowns. The beads were washed four times with 0.1% w/v DDM in PBS. The protein from the beads were either eluted with Laemmli buffer with DTT and boiled for 5 min or eluted with Laemmli buffer without DTT and reduced with DTT for 30 min at 37 °C after separating the beads from the sample. The eluted proteins or whole cell lysates were separated by SDS-PAGE on a 4–20% gradient gel (Bio-Rad) and transferred to polyvinylidene fluoride membranes. The membranes were blocked overnight at 4 °C with 5% BSA in Tris-buffered saline with 0.1% Tween 20 (TBST). Either mouse M2 FLAG or mouse HA-7 primary antibodies (Sigma-Aldrich) were used at a 1:1000 dilution in 2.5% BSA in TBST for 1 h at room temperature. The blots were washed (four times for 3 min) with TBST. A secondary goat anti-mouse horseradish peroxidase-conjugated antibody (Abcam, Cambridge, UK) was used at a 1:10,000 dilution for 1 h at room temperature. The blots were washed (four times for 3 min) with TBST before adding the ECL Western blotting substrate (Pierce). The blots were imaged using a ChemiDoc<sup>TM</sup> XRS+ system and analyzed using Image Lab<sup>TM</sup> software (Bio-Rad).

### Immunostaining and confocal microscopy

HEK293T cells were plated in 8-well chamber slides (ibidi GmbH, Martinsreid, Planegg, Germany) previously coated with poly-D-lysine. The cells were transfected with either N-terminally FLAG-tagged MRAP2 or MRAP2  $\Delta$ 38–44 and C-terminally FLAG-tagged MRAP2 or MRAP2  $\Delta$ 38–44. After 24 h post-transfection, the transfected cells were washed twice with ice-cold PBS and fixed with 2% formaldehyde in PBS for 10 min at room temperature. The cells were washed with PBS (three times for 5 min), and permeabilized samples were incubated with 0.5% saponin in PBS for 10 min. Unpermeabilized cells

were incubated with PBS for 10 min. The cells were washed with PBS (three times for 5 min). The cells were then blocked with 1% BSA in PBS for unpermeabilized cells or 1% BSA, 0.1% saponin in PBS for permeabilized cells for 30 min. Blocked cells were then incubated with a mouse M2 FLAG antibody (Sigma-Aldrich) at a 1:600 dilution in 1% BSA in PBS for 1 h. The cells were washed again with PBS (three times for 5 min) and incubated with a goat anti-mouse Alexa 568 antibody (highly cross-adsorbed) (Invitrogen) at a 1:1000 dilution in 1% BSA in PBS for 1 h in the dark. For the fixation control experiments, the cells were incubated with an  $\alpha$ -tubulin mAb conjugated to Alexa Fluor 488 (B-5-1-2; Invitrogen) at 2  $\mu$ g/ml in 1% BSA in PBS for 1 h. The cells were washed with PBS (three times for 5 min), stained with Hoechst 33342 (5  $\mu$ g/ml) (Invitrogen) for 1 min, and washed with PBS again (three times for 5 min), and the slides were mounted with Fluoromount-G mounting medium (SouthernBiotech, Birmingham, AL, USA). Images were acquired on a Leica SP5 confocal microscope and analyzed by Fiji ImageJ.

### Immunostaining and flow cytometry

HEK293T cells were transfected with either N-terminally FLAG-tagged MRAP2 or MRAP2  $\Delta$ 38–44, C-terminally FLAG-tagged MRAP2 or MRAP2  $\Delta$ 38–44, N-terminally HA-tagged RAMP3, or C-terminally HA-tagged RAMP3. After 24 h post-transfection, transfected cells were washed twice with ice-cold PBS and fixed with 2% formaldehyde in PBS for 10 min at room temperature. Fixed cells were then washed twice with PBS and split into two separate samples. Each of the samples was further washed with either FACS buffer without Triton X-100 (PBS, pH 7.4, 1% BSA, 1 mM EDTA, 0.05% sodium azide) for nonpermeabilized samples or FACS buffer with Triton X-100 (PBS, pH 7.4, 1% BSA, 1 mM EDTA, 0.05% sodium azide, 0.1% Triton X-100) for permeabilized samples. Unpermeabilized cells were resuspended in FACS buffer, and permeabilized cells were resuspended in FACS buffer with Triton X-100. Alexa Fluor 488-conjugated anti-HA (Cell Signaling Technologies, catalog no. 2350) or anti-FLAG (Cell Signaling Technologies, catalog no. 15008) antibodies were added at a 1:50 dilution, and the cells were incubated with the fluorescent antibodies for 1 h in the dark at 4 °C. Stained cells were then washed with FACS buffer three times and resuspended in FACS buffer before flow analysis. The cells were analyzed on a BD LSR II, and 10,000 cells were counted and analyzed for each sample. FlowJo was used for data processing. The median fluorescence intensity value for the unpermeabilized cells was divided by the median fluorescence intensity of the permeabilized samples to normalize for differences in protein expression levels.

### NanoBiT protein-protein interaction assay

HEK293T cells were plated in an opaque, white 96-well plate. The cells were transfected with Lipofectamine 2000 according to the manufacturer's instructions. After 24 h post-transfection, the medium was removed and replaced with Opti-MEM (Life Technologies). NanoBiT live-cell substrate was added according to manufacturer's instructions and incubated for 5

## Membrane oligomerization of MRAP

min. Luminescence was measured using a PerkinElmer EnVision plate reader.

### Whole-cell cross-linking

HEK293T cells were transfected with 3×FLAG-MRAP2. After 24 h post-transfection, the cells were washed with PBS and incubated with 1 mM disuccinimidyl suberate or disuccinimidyl glutarate (Thermo Fisher) in PBS for 30 min at room temperature. The cross-linking reaction was quenched with 30 mM Tris-HCl in PBS for 10 min. The cells were then pelleted and washed with 30 mM Tris-HCl in PBS. The washed cell pellet was lysed with 1% DDM in PBS and analyzed by SDS-PAGE and Western blotting as described under “Co-immunoprecipitation and Western blotting.”

### Native protein gel electrophoresis and Western blotting

HEK293T cells were transfected with 3×FLAG-MRAP2. At 24 h post-transfection, the cells were washed with PBS and lysed with a native lysis buffer (50 mM BisTris, pH 7.2, 50 mM NaCl, 10% glycerol) with protease inhibitors and varying concentrations of DDM for 30 min on ice. Lysates were clarified at  $17,000 \times g$  at 4°C for 25 min. Protein concentrations were determined using a BCA protein quantitation kit (Pierce) according to the manufacturer's instructions. A 10× loading dye (5% w/v Coomassie Blue G-250, 500 mM 6-aminohexanoic acid) was added to lysates right before loading samples into a NativePAGE BisTris gel 4–16% (Life Technologies, Inc.). The proteins were separated according to Wittig *et al.* (33) and transferred onto a polyvinylidene fluoride membrane using a standard Tris-glycine transfer buffer with 0.05% SDS. The membrane was destained in methanol for 3 min. The membrane was blocked and immunoblotted as described under “Co-immunoprecipitation and Western blotting.”

### Data availability

All data for this study are available within the article.

**Acknowledgments**—We thank Professor Julien A. Sebag for advice and expertise regarding MRAP2, Ben Abrams for microscopy support, and Bari H. Nazario for help with flow cytometry. We also thank Dr. Kevin Schilling for valuable assistance with data analysis.

**Author contributions**—V. C. and G. L. M. conceptualization; V. C. and G. L. M. data curation; V. C. and G. L. M. formal analysis; V. C., R. D. C., and G. L. M. validation; V. C., A. E. B., L. L. B., C. C. H., L. E. G., A. P., R. D. C., and G. L. M. investigation; V. C. visualization; V. C., R. D. C., and G. L. M. methodology; V. C. and G. L. M. writing-original draft; V. C. and G. L. M. writing-review and editing; R. D. C. and G. L. M. funding acquisition; G. L. M. supervision; G. L. M. project administration.

**Funding and additional information**—This work was supported by National Institutes of Health Grants R01DK110403 (to G. L. M.) and R01DK070332 (to R. D. C.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: MRAP, melanocortin receptor accessory protein; GPCR, G protein-coupled receptor; MC4R, melanocortin-4 receptor; GHSR, growth hormone secretagogue receptor; CHO, Chinese hamster ovary; TM, transmembrane domain; NTD, N-terminal domain; CTD, C-terminal domain; OX1R, orexin receptor 1; PKR1, prokineticin receptor 1; YFP, yellow fluorescent protein; DDM, *n*-dodecyl- $\beta$ -maltoside.

### References

1. Asai, M., Ramachandrapa, S., Joachim, M., Shen, Y., Zhang, R., Nuthalapati, N., Ramanathan, V., Strohlic, D. E., Ferket, P., Linhart, K., Ho, C., Novoselova, T. V., Garg, S., Ridderstråle, M., Marcus, C., *et al.* (2013) Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. *Science* **341**, 275–278 [CrossRef Medline](#)
2. Geets, E., Zegers, D., Beckers, S., Verrijken, A., Massa, G., Van Hoorenbeeck, K., Verhulst, S., Van Gaal, L., and Van Hul, W. (2016) Copy number variation (CNV) analysis and mutation analysis of the 6q14.1–6q16.3 genes SIM1 and MRAP2 in Prader Willi like patients. *Mol. Genet. Metab.* **117**, 383–388 [CrossRef Medline](#)
3. Schonnop, L., Kleinau, G., Herrfurth, N., Volckmar, A. L., Cetindag, C., Müller, A., Peters, T., Herpertz, S., Antel, J., Hebebrand, J., Biebrermann, H., and Hinney, A. (2016) Decreased melanocortin-4 receptor function conferred by an infrequent variant at the human melanocortin receptor accessory protein 2 gene. *Obesity* **24**, 1976–1982 [CrossRef Medline](#)
4. Baron, M., Mailliet, J., Huyvaert, M., Dechaume, A., Boutry, R., Loiselle, H., Durand, E., Toussaint, B., Vaillant, E., Philippe, J., Thomas, J., Ghulam, A., Franc, S., Charpentier, G., Borys, J. M., *et al.* (2019) Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. *Nat. Med.* **25**, 1733–1738 [CrossRef Medline](#)
5. Sebag, J. A., Zhang, C., Hinkle, P. M., Bradshaw, A. M., and Cone, R. D. (2013) Developmental control of the melanocortin-4 receptor by MRAP2 proteins in zebrafish. *Science* **341**, 278–281 [CrossRef Medline](#)
6. Farooqi, I. S., Yeo, G. S., Keogh, J. M., Aminian, S., Jebb, S. A., Butler, G., Cheetham, T., and O'Rahilly, S. (2000) Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. *J. Clin. Invest.* **106**, 271–279 [CrossRef Medline](#)
7. Vaisse, C., Clement, K., Durand, E., Hercberg, S., Guy-Grand, B., and Froguel, P. (2000) Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. *J. Clin. Invest.* **106**, 253–262 [CrossRef Medline](#)
8. Bruschetta, G., Kim, J. D., Diano, S., and Chan, L. F. (2018) Overexpression of melanocortin 2 receptor accessory protein 2 (MRAP2) in adult paraventricular MC4R neurons regulates energy intake and expenditure. *Mol. Metab.* **18**, 79–87 [CrossRef Medline](#)
9. Chaly, A. L., Srisai, D., Gardner, E. E., and Sebag, J. A. (2016) The melanocortin receptor accessory protein 2 promotes food intake through inhibition of the prokineticin receptor-1. *eLife* **5**, e12397 [CrossRef Medline](#)
10. Rouault, A. A. J., Lee, A. A., and Sebag, J. A. (2017) Regions of MRAP2 required for the inhibition of orexin and prokineticin receptor signaling. *Biochim. Biophys. Acta Mol. Cell Res.* **1864**, 2322–2329 [CrossRef Medline](#)
11. Srisai, D., Yin, T. C., Lee, A. A., Rouault, A. A. J., Pearson, N. A., Grobe, J. L., and Sebag, J. A. (2017) MRAP2 regulates ghrelin receptor signaling and hunger sensing. *Nat. Commun.* **8**, 713 [CrossRef Medline](#)
12. Rouault, A. A. J., Rosselli-Murai, L. K., Hernandez, C. C., Gimenez, L. E., Tall, G. G., and Sebag, J. A. (2020) The GPCR accessory protein MRAP2 regulates both biased signaling and constitutive activity of the ghrelin receptor GHSR1a. *Sci. Signal.* **13**, eaax4569 [CrossRef Medline](#)
13. Sebag, J. A., and Hinkle, P. M. (2009) Regions of melanocortin 2 (MC2) receptor accessory protein necessary for dual topology and MC2 receptor trafficking and signaling. *J. Biol. Chem.* **284**, 610–618 [CrossRef Medline](#)
14. Hinkle, P. M., and Sebag, J. A. (2009) Structure and function of the melanocortin2 receptor accessory protein MRAP. *Mol. Cell Endocrinol.* **300**, 25–31 [CrossRef Medline](#)

15. Sebag, J. A., and Hinkle, P. M. (2007) Melanocortin-2 receptor accessory protein MRAP forms antiparallel homodimers. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 20244–20249 [CrossRef Medline](#)
16. Sebag, J. A., and Hinkle, P. M. (2010) Regulation of G protein-coupled receptor signaling: specific dominant-negative effects of melanocortin 2 receptor accessory protein 2. *Sci. Signal.* **3**, ra28 [CrossRef Medline](#)
17. Chan, L. F., Webb, T. R., Chung, T. T., Meimaridou, E., Cooray, S. N., Guasti, L., Chapple, J. P., Egertova, M., Elphick, M. R., Cheetham, M. E., Metherell, L. A., and Clark, A. J. (2009) MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 6146–6151 [CrossRef Medline](#)
18. Heijne, G. (1986) The distribution of positively charged residues in bacterial inner membrane proteins correlates with the trans-membrane topology. *EMBO J.* **5**, 3021–3027 [CrossRef Medline](#)
19. Hartmann, E., Rapoport, T. A., and Lodish, H. F. (1989) Predicting the orientation of eukaryotic membrane-spanning proteins. *Proc. Natl. Acad. Sci. U.S.A.* **86**, 5786–5790 [CrossRef Medline](#)
20. McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., and Foord, S. M. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* **393**, 333–339 [CrossRef Medline](#)
21. Teese, M. G., and Langosch, D. (2015) Role of GXXXG motifs in transmembrane domain interactions. *Biochemistry* **54**, 5125–5135 [CrossRef Medline](#)
22. Senes, A., Gerstein, M., and Engelman, D. M. (2000) Statistical analysis of amino acid patterns in transmembrane helices: the GXXXG motif occurs frequently and in association with  $\beta$ -branched residues at neighboring positions. *J. Mol. Biol.* **296**, 921–936 [CrossRef Medline](#)
23. Wittig, I., Beckhaus, T., Wumaier, Z., Karas, M., and Schägger, H. (2010) Mass estimation of native proteins by blue native electrophoresis. *Mol. Cell. Proteomics* **9**, 2149–2161 [CrossRef Medline](#)
24. Heuberger, E. H. M. L., Veenhoff, L. M., Duurkens, R. H., Friesen, R. H. E., and Poolman, B. (2002) Oligomeric state of membrane transport proteins analyzed with blue native electrophoresis and analytical ultracentrifugation. *J. Mol. Biol.* **317**, 591–600 [CrossRef Medline](#)
25. Rapp, M., Granseth, E., Seppälä, S., and Heijne, G. V. (2006) Identification and evolution of dual-topology membrane proteins. *Nat. Struct. Mol. Biol.* **13**, 112–116 [CrossRef Medline](#)
26. Sonnhammer, E. L., von Heijne, G., and Krogh, A. (1998) A hidden Markov model for predicting transmembrane helices in protein sequences. *Proc. Int. Conf. Intell. Syst. Mol. Biol.* **6**, 175–182 [Medline](#)
27. Hilaret, S., Bélanger, C., Bertrand, J., Laperrière, A., Foord, S. M., and Bouvier, M. (2001) Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and  $\beta$ -arrestin. *J. Biol. Chem.* **276**, 42182–42190 [CrossRef Medline](#)
28. Malik, S., Dolan, T. M., Maben, Z. J., and Hinkle, P. M. (2015) Adrenocorticotrophic hormone (ACTH) responses require actions of the melanocortin-2 receptor accessory protein on the extracellular surface of the plasma membrane. *J. Biol. Chem.* **290**, 27972–27985 [CrossRef Medline](#)
29. Walters, R. F., and DeGrado, W. F. (2006) Helix-packing motifs in membrane proteins. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 13658–13663 [CrossRef Medline](#)
30. Elbaz, Y., Salomon, T., and Schuldiner, S. (2008) Identification of a glycine motif required for packing in EmrE, a multidrug transporter from *Escherichia coli*. *J. Biol. Chem.* **283**, 12276–12283 [CrossRef Medline](#)
31. Swanton, E., Holland, A., High, S., and Woodman, P. (2005) Disease-associated mutations cause premature oligomerization of myelin proteolipid protein in the endoplasmic reticulum. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 4342–4347 [CrossRef Medline](#)
32. Bugge, K., Lindorff-Larsen, K., and Kragelund, B. B. (2016) Understanding single-pass transmembrane receptor signaling from a structural viewpoint: what are we missing? *FEBS J.* **283**, 4424–4451 [CrossRef Medline](#)
33. Wittig, I., Braun, H.-P., and Schägger, H. (2006) Blue native PAGE. *Nat. Protoc.* **1**, 418–428 [CrossRef Medline](#)